Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia.

Tosello V, Milani G, Martines A, Macri N, Van Loocke W, Matthijssens F, Buldini B, Minuzzo S, Bongiovanni D, Schumacher RF, Amadori A, Van Vlierberghe P, Piovan E.

Cells. 2018 Oct 9;7(10). pii: E160. doi: 10.3390/cells7100160.

2.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

3.

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.

Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ 3rd, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P.

Br J Haematol. 2018 Jun 25. doi: 10.1111/bjh.15425. [Epub ahead of print] No abstract available.

PMID:
29938777
4.

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, Lintermans B, Dobay MP, Berx G, Poppe B, Goossens S, Bornhauser BC, Bourquin JP, Van Vlierberghe P.

Leukemia. 2017 Oct;31(10):2037-2047. doi: 10.1038/leu.2017.10. Epub 2017 Jan 11.

5.

Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.

Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F, Sonderegger SE, Haigh K, Nguyen T, Vandamme N, Costa M, Carmichael C, Van Nieuwerburgh F, Deforce D, Kleifeld O, Curtis DJ, Berx G, Van Vlierberghe P, Haigh JJ.

Blood. 2017 Feb 23;129(8):981-990. doi: 10.1182/blood-2016-06-721191. Epub 2017 Jan 9.

6.

Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.

Wallaert A, Durinck K, Van Loocke W, Van de Walle I, Matthijssens F, Volders PJ, Avila Cobos F, Rombaut D, Rondou P, Mestdagh P, Vandesompele J, Poppe B, Taghon T, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2016 Sep;30(9):1927-30. doi: 10.1038/leu.2016.82. Epub 2016 Apr 22. No abstract available.

PMID:
27168467
7.

Novel biological insights in T-cell acute lymphoblastic leukemia.

Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, Pieters T, Milani G, Lammens T, Rondou P, Van Roy N, De Moerloose B, Benoit Y, Haigh J, Speleman F, Poppe B, Van Vlierberghe P.

Exp Hematol. 2015 Aug;43(8):625-39. doi: 10.1016/j.exphem.2015.05.017. Epub 2015 Jun 26. Review.

PMID:
26123366
8.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ.

Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794.

9.

The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.

Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, Delabesse E, Lammens T, De Moerloose B, Menten B, Van Roy N, Verhasselt B, Poppe B, Benoit Y, Taghon T, Melnick AM, Speleman F, Wendel HG, Van Vlierberghe P.

Blood. 2015 Jan 1;125(1):13-21. doi: 10.1182/blood-2014-05-577270. Epub 2014 Oct 15.

10.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

11.

Anthranilate fluorescence marks a calcium-propagated necrotic wave that promotes organismal death in C. elegans.

Coburn C, Allman E, Mahanti P, Benedetto A, Cabreiro F, Pincus Z, Matthijssens F, Araiz C, Mandel A, Vlachos M, Edwards SA, Fischer G, Davidson A, Pryor RE, Stevens A, Slack FJ, Tavernarakis N, Braeckman BP, Schroeder FC, Nehrke K, Gems D.

PLoS Biol. 2013 Jul;11(7):e1001613. doi: 10.1371/journal.pbio.1001613. Epub 2013 Jul 23.

12.

ROS in aging Caenorhabditis elegans: damage or signaling?

Back P, Braeckman BP, Matthijssens F.

Oxid Med Cell Longev. 2012;2012:608478. doi: 10.1155/2012/608478. Epub 2012 Aug 15. Review.

13.

A simplified hydroethidine method for fast and accurate detection of superoxide production in isolated mitochondria.

Back P, Matthijssens F, Vanfleteren JR, Braeckman BP.

Anal Biochem. 2012 Apr 1;423(1):147-51. doi: 10.1016/j.ab.2012.01.008. Epub 2012 Jan 24.

PMID:
22310498
14.

Exploring real-time in vivo redox biology of developing and aging Caenorhabditis elegans.

Back P, De Vos WH, Depuydt GG, Matthijssens F, Vanfleteren JR, Braeckman BP.

Free Radic Biol Med. 2012 Mar 1;52(5):850-9. doi: 10.1016/j.freeradbiomed.2011.11.037. Epub 2011 Dec 23.

PMID:
22226831
15.

DamID in C. elegans reveals longevity-associated targets of DAF-16/FoxO.

Schuster E, McElwee JJ, Tullet JM, Doonan R, Matthijssens F, Reece-Hoyes JS, Hope IA, Vanfleteren JR, Thornton JM, Gems D.

Mol Syst Biol. 2010 Aug 10;6:399. doi: 10.1038/msb.2010.54.

16.

Disruption of insulin signalling preserves bioenergetic competence of mitochondria in ageing Caenorhabditis elegans.

Brys K, Castelein N, Matthijssens F, Vanfleteren JR, Braeckman BP.

BMC Biol. 2010 Jun 28;8:91. doi: 10.1186/1741-7007-8-91.

17.

Effects of sod gene overexpression and deletion mutation on the expression profiles of reporter genes of major detoxification pathways in Caenorhabditis elegans.

Back P, Matthijssens F, Vlaeminck C, Braeckman BP, Vanfleteren JR.

Exp Gerontol. 2010 Aug;45(7-8):603-10. doi: 10.1016/j.exger.2010.01.014. Epub 2010 Jan 22.

PMID:
20096764
18.

Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans.

Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, Back P, Matscheski A, Vanfleteren JR, Gems D.

Genes Dev. 2008 Dec 1;22(23):3236-41. doi: 10.1101/gad.504808.

19.

Prooxidant activity of the superoxide dismutase (SOD)-mimetic EUK-8 in proliferating and growth-arrested Escherichia coli cells.

Matthijssens F, Back P, Braeckman BP, Vanfleteren JR.

Free Radic Biol Med. 2008 Sep 1;45(5):708-15. doi: 10.1016/j.freeradbiomed.2008.05.023. Epub 2008 Jun 4.

PMID:
18573332
20.

Selection and validation of a set of reliable reference genes for quantitative sod gene expression analysis in C. elegans.

Hoogewijs D, Houthoofd K, Matthijssens F, Vandesompele J, Vanfleteren JR.

BMC Mol Biol. 2008 Jan 22;9:9. doi: 10.1186/1471-2199-9-9.

21.

Metabolism, physiology and stress defense in three aging Ins/IGF-1 mutants of the nematode Caenorhabditis elegans.

Houthoofd K, Fidalgo MA, Hoogewijs D, Braeckman BP, Lenaerts I, Brys K, Matthijssens F, De Vreese A, Van Eygen S, Muñoz MJ, Vanfleteren JR.

Aging Cell. 2005 Apr;4(2):87-95.

22.

DAF-2 pathway mutations and food restriction in aging Caenorhabditis elegans differentially affect metabolism.

Houthoofd K, Braeckman BP, Lenaerts I, Brys K, Matthijssens F, De Vreese A, Van Eygen S, Vanfleteren JR.

Neurobiol Aging. 2005 May;26(5):689-96.

PMID:
15708444
23.

Superoxide dismutase mimetics elevate superoxide dismutase activity in vivo but do not retard aging in the nematode Caenorhabditis elegans.

Keaney M, Matthijssens F, Sharpe M, Vanfleteren J, Gems D.

Free Radic Biol Med. 2004 Jul 15;37(2):239-50.

PMID:
15203195
24.

A Bcl-2 transgene expressed in hepatocytes does not protect mice from fulminant liver destruction induced by Fas ligand.

Loo Gv, Lippens S, Hahne M, Matthijssens F, Declercq W, Saelens X, Vandenabeele P.

Cytokine. 2003 May;22(3-4):62-70.

PMID:
12849704
25.

A high-throughput microtiter plate assay for superoxide dismutase based on lucigenin chemiluminescence.

Lenaerts I, Braeckman BP, Matthijssens F, Vanfleteren JR.

Anal Biochem. 2002 Dec 1;311(1):90-2. No abstract available.

PMID:
12441159
26.

Caspases are not localized in mitochondria during life or death.

van Loo G, Saelens X, Matthijssens F, Schotte P, Beyaert R, Declercq W, Vandenabeele P.

Cell Death Differ. 2002 Nov;9(11):1207-11.

Supplemental Content

Loading ...
Support Center